Evidence Brief: Detection and Treatment of Dental Problems on Chronic Disease Outcomes

February 2021

Prepared for:
Department of Veterans Affairs
Veterans Health Administration
Health Services Research & Development Service
Washington, DC 20420

Prepared by:
Evidence Synthesis Program (ESP)
Coordinating Center
Portland VA Health Care System
Portland, OR
Mark Helfand, MD, MPH, MS, Director

Authors:
Stephanie Veazie, MPH
Kathryn Vela, MLIS
Nicholas J. Parr, PhD, MPH
PREFACE

The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The program comprises three ESP Centers across the US and a Coordinating Center located in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Center Program and Cochrane. The Coordinating Center was created to manage program operations, ensure methodological consistency and quality of products, and interface with stakeholders. To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee composed of health system leadership and researchers. The program solicits nominations for review topics several times a year via the program website.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Nicole.Floyd@va.gov.


This report is based on research conducted by the Evidence Synthesis Program (ESP) Center located at the VA Portland Health Care System funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>1</td>
</tr>
<tr>
<td>Key Findings</td>
<td>1</td>
</tr>
<tr>
<td>Evidence Brief</td>
<td>6</td>
</tr>
<tr>
<td>Introduction</td>
<td>6</td>
</tr>
<tr>
<td>Purpose</td>
<td>6</td>
</tr>
<tr>
<td>Background</td>
<td>6</td>
</tr>
<tr>
<td>Scope</td>
<td>8</td>
</tr>
<tr>
<td>Key Questions</td>
<td>8</td>
</tr>
<tr>
<td>Eligibility Criteria</td>
<td>9</td>
</tr>
<tr>
<td>Methods</td>
<td>11</td>
</tr>
<tr>
<td>Searches and Study Selection</td>
<td>11</td>
</tr>
<tr>
<td>Quality Assessment and Data Extraction</td>
<td>12</td>
</tr>
<tr>
<td>Strength of Evidence Assessment</td>
<td>12</td>
</tr>
<tr>
<td>Synthesis of Data</td>
<td>12</td>
</tr>
<tr>
<td>Results</td>
<td>13</td>
</tr>
<tr>
<td>Literature Flow</td>
<td>15</td>
</tr>
<tr>
<td>Type 2 Diabetes</td>
<td>16</td>
</tr>
<tr>
<td>Overview</td>
<td>16</td>
</tr>
<tr>
<td>Patient-reported Symptoms and Complications</td>
<td>16</td>
</tr>
<tr>
<td>Chronic Disease Indicators</td>
<td>19</td>
</tr>
<tr>
<td>Health Care Utilization and Costs</td>
<td>20</td>
</tr>
<tr>
<td>Harms</td>
<td>22</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>22</td>
</tr>
<tr>
<td>Overview</td>
<td>22</td>
</tr>
<tr>
<td>Patient-reported Symptoms and Complications</td>
<td>23</td>
</tr>
<tr>
<td>Chronic Disease Indicators</td>
<td>23</td>
</tr>
<tr>
<td>Health Care Utilization and Costs</td>
<td>25</td>
</tr>
<tr>
<td>Harms</td>
<td>25</td>
</tr>
<tr>
<td>Cerebrovascular Disease</td>
<td>26</td>
</tr>
<tr>
<td>Overview</td>
<td>26</td>
</tr>
<tr>
<td>Patient-reported Symptoms and Complications</td>
<td>26</td>
</tr>
<tr>
<td>Chronic Disease Indicators</td>
<td>26</td>
</tr>
<tr>
<td>Health Care Utilization and Costs</td>
<td>26</td>
</tr>
</tbody>
</table>
Evidence Brief: Detection and Treatment of Dental Problems

Harms ......................................................................................................................................... 26
Chronic Obstructive Pulmonary Disease (COPD) ...................................................................... 27
Overview .................................................................................................................................... 27
Patient-reported Symptoms and Complications ......................................................................... 27
Chronic Disease Indicators ........................................................................................................ 28
Health Care Utilization, Costs, and Harms ................................................................................ 28
Summary and Discussion .............................................................................................................. 29
Limitations ................................................................................................................................... 31
Rapid Review Limitations ......................................................................................................... 31
Limitations of Included Studies ................................................................................................. 31
Gaps and Future Research ........................................................................................................... 31
Conclusions ................................................................................................................................... 33
Acknowledgments ......................................................................................................................... 34
Operational Partners ..................................................................................................................... 34
References ..................................................................................................................................... 35

TABLES AND FIGURES
Table 1. Highlighted Review Findings .......................................................................................... 3
Figure 1. Conceptual Pathway between Receipt of Preventive Dental Services and Improvement in Chronic Disease Outcomes ......................................................................................................................... 8
Figure 2. Analytic Framework of Key Questions and PICOs ..................................................... 10
Figure 3: Literature Flowchart ..................................................................................................... 15
Table 2. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With T2 Diabetes .............................................................................................................. 17
Table 3. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Cardiovascular Disease ......................................................................................... 24
Table 4. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Cerebrovascular Disease .................................................................................... 27
Table 5. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Chronic Obstructive Pulmonary Disease ......................................................... 28
EXECUTIVE SUMMARY

Key Findings

- For adults with chronic obstructive pulmonary disease (COPD), periodontal treatment may improve lung function and reduce the frequency of exacerbations at 1 and 2 years compared to no treatment based on 2 fair-quality controlled trials. Periodontal treatment may also contribute to lower annual medical costs based on 1 poor-quality retrospective cohort study.

- For adults with type 2 diabetes, periodontal treatment likely improves measures of chronic disease severity and inflammation (e.g., HbA1c, fasting blood glucose, total cholesterol, CRP) with only minor adverse events in the short term (3-4 months) based on several moderate- and high-quality systematic reviews and newly published RCTs. These improvements do not appear to persist beyond 6 months, however. Findings are unclear on the relation between periodontal treatment and diabetes-related complications and costs.

- For adults with cardiovascular disease, periodontal treatment likely improves measures of inflammation (e.g., TNF-α, IL-6 and CRP) at 3 months based on 1 moderate- and 1 high-quality systematic review; longer-term outcomes have not been evaluated. Findings are unclear on the relation between periodontal treatment and cardiovascular-related complications and costs.

- There is limited available evidence on the effect of periodontal treatment among adults with cerebrovascular disease. Existing studies are unclear on the relation of periodontal treatment to complications and costs, similar to findings for diabetes and cardiovascular disease.

Poor dental health in the form of periodontal disease (a gum infection typically caused by poor oral hygiene) is a widespread issue in the United States. Nearly half of US adults aged 30 and older have periodontal disease, and prevalence is highest among older adults (70% of those 65 or older), men (56%), smokers (64%), and those below the federal poverty level (65%). In the last 2 decades, growing evidence has suggested periodontal disease is associated with chronic diseases such as heart disease, lung disease, stroke, and type 2 diabetes. The pathway between periodontal disease and chronic diseases is not well understood, but periodontal disease may trigger an inflammatory response in the body that leads to high blood pressure, vascular inflammation, and/or...
atherosclerosis; these processes then contribute to the etiology and severity of certain chronic diseases. Bacteria in the oral cavity may also be inhaled into the lower respiratory tract, leading to exacerbations of chronic obstructive pulmonary disease (COPD).

Detection and initial treatment of dental problems, including periodontal disease, is commonly implemented through the provision of preventive dental services such as routine exams, cleanings, and education on oral hygiene. Treatment of more advanced forms of periodontal disease typically consists of scaling and root planing, with or without the use of antibiotics. Currently, few Veterans receive these services: only 8% of Veterans have a dental issue that is service-connected, or meet other criteria required to receive dental care through the Department of Veterans Affairs (VA). In 2019, the VA initiated the Veterans Innovation Center (VIC) Care Coordination for Dental Benefits program to increase Veterans’ access to community-based, pro bono or discounted dental service providers. Although the intended purpose of the program is to reduce the use of VA emergency care for dental conditions by providing Veterans with access to routine dental care, the program may also improve Veterans’ chronic disease outcomes, given the link between periodontal disease treatment and chronic disease outcomes. The purpose of the current ESP review is to synthesize evidence on benefits and harms of detection and treatment of dental problems (specifically, periodontal disease) among those with type 2 diabetes, cardiovascular disease, cerebrovascular disease, or COPD. Evidence on chronic disease outcomes, health care utilization, and costs associated with periodontal treatment will be used to inform the implementation and evaluation of the VA Care Coordination for Dental Benefits program.

Using rapid review methods, we prioritized evidence from the most recent and relevant systematic reviews (SRs) and only included primary studies when they addressed gaps in higher-level evidence and when they were published after the search dates of prioritized SRs. From 1,768 possible citations, we included 46 studies; from these, we prioritized 8 SRs and included 21 primary studies that addressed gaps or updated evidence from SRs. Highlighted findings from these 29 studies appears in Table 1.

For those with COPD, evidence from 3 controlled trials suggests that periodontal treatment improves certain chronic disease outcomes. One fair-quality RCT and 1 fair-quality non-randomized, controlled trial indicate periodontal treatment may improve lung function and reduce the frequency of exacerbations at 1 and 2 years compared to no treatment. Another fair-quality RCT found no adverse events within a month of periodontal treatment. However, in this short study, periodontal treatment did not reduce the number of doctor’s visits after treatment, nor did it improve quality of life, self-assessment of health, or illness severity. An additional poor-quality retrospective cohort study indicated those with COPD who receive periodontal treatment have lower annual medical costs than those who do not receive treatment.

Results from moderate- and high-quality SRs suggest periodontal treatment improves some chronic disease and inflammatory indicators in the short term for people with type 2 diabetes (eg, HbA1c, fasting blood glucose, total cholesterol, CRP) or cardiovascular disease (eg, TNF-α, IL-6, CRP, LDL cholesterol) with only minor adverse events. However, improvements do not seem to last beyond 6 months. The impact of periodontal treatment on chronic disease indicators for those with cerebrovascular disease is unclear.
Table 1. Highlighted Review Findings

<table>
<thead>
<tr>
<th>Patient-reported symptoms and complications</th>
<th>Type 2 Diabetes</th>
<th>Cardiovascular disease</th>
<th>Cerebrovascular disease</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unclear results on OHRQoL at 3 mo</td>
<td>Pts with hypertension or atherosclerosis: ↓ risk of stroke over 10 yrs</td>
<td>Pts who experienced stroke: Risk of stroke is higher after periodontal tx than at baseline</td>
<td>↓ Frequency of COPD exacerbations at 1 and 2 yrs</td>
</tr>
<tr>
<td>No difference in functionality at 3 mo</td>
<td>Pts who experienced MI: Risk of MI higher after periodontal tx than at baseline</td>
<td></td>
<td>No difference in COPD-related QoL, self-assessment of health, or illness severity at 1 mo</td>
<td></td>
</tr>
<tr>
<td>↓ Risk of heart failure over 3 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unclear results on risk of stroke/MI over 3 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic disease indicators</td>
<td>↓ HbA1c at 3 mo, no difference at 6 mo</td>
<td>Pts with chronic heart disease: ↓ TNF-α, IL-6 and CRP at 3 mo</td>
<td>No data available</td>
<td>↑ FEV1 and FEV1/FVC at 2 yrs</td>
</tr>
<tr>
<td>↓ FBG at 3-6 mo</td>
<td>Pts with hyperlipidemia: ↓ LDL cholesterol and CRP at 3 mo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓ Total cholesterol, ↓ triglycerides, and ↑ HDL cholesterol at 3 mo; no difference at 6 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓ CRP at 3-6 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No difference in LDL cholesterol at 3 or 6 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unclear results on IL-6 and other measures of systematic inflammation at 3-6 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthcare utilization and costs</td>
<td>Unclear results on medical costs over max of 7 yrs</td>
<td>Pts with CAD: Unclear results on medical costs over max of 5 yrs</td>
<td>Unclear results on medical costs over max of 5 yrs</td>
<td>No difference in doctor’s visits at 1 mo</td>
</tr>
<tr>
<td>Unclear results on healthcare utilization over max of 5 yrs</td>
<td>Pts with CHD: ↓ Annual medical costs</td>
<td>↓ Inpatient admissions over max of 5 yrs</td>
<td>↓ Annual medical costs</td>
<td></td>
</tr>
<tr>
<td>Harms</td>
<td>Periodontal treatment group experienced minor adverse events (eg, diarrhea, headaches, nausea) at 3-6 mo</td>
<td>No data available</td>
<td>No data available</td>
<td>Periodontal treatment group experienced no adverse events at 1 mo</td>
</tr>
</tbody>
</table>

All results in the table represent differences in outcomes between periodontal treatment and no treatment groups at follow-up unless otherwise specified. Key: OHRQoL=Oral health-related quality of life, Yrs=Years, MI=Myocardial infarction, Pts=Patients, Tx=Treatment, COPD=Chronic obstructive pulmonary disease, QoL=Quality of life, Mo=Month, FBG=Fasting blood glucose, HDL=High density lipoproteins, LDL=Low density lipoproteins, CRP=C-reactive Protein, FEV1=Forced expiratory volume in the first second, FVC=Forced vital capacity, CAD=Coronary artery disease, CHD=Congestive Heart Failure. Color scheme: Moderate SOE; Low SOE; Insufficient SOE
Evidence is also unclear on whether periodontal treatment reduces the risk of diabetes and cardiovascular disease-related complications. For those with type 2 diabetes, evidence from a single fair-quality retrospective cohort study indicates periodontal treatment may reduce the risk of heart failure compared to no treatment. Findings on stroke and myocardial infarction are unclear, with some studies finding lower risk among people with type 2 diabetes who receive periodontal treatment compared to no treatment and others finding no difference in risk between groups. For those with hypertension or atherosclerosis, evidence from a single, poor-quality retrospective cohort study indicates periodontal treatment is associated with a reduced risk of stroke. However, a self-controlled case series indicates that individuals’ risk for stroke and myocardial infarction actually increased after periodontal treatment when compared to baseline. It is possible the results of this study were influenced by patients discontinuing NSAIDS, blood thinners, or antiplatelet medications due to periodontal treatment, which could have caused an increase in cardiovascular risk. In this study, the risk of MI decreased over time, while for stroke, the pattern of resolution was unclear.

Findings on costs of periodontal treatment versus no treatment for people with type 2 diabetes, coronary artery disease (CAD), or cerebrovascular disease are similarly unclear, with some studies indicating periodontal treatment contributes to lower medical costs and other studies indicating periodontal treatment has no effect or contributes to higher health care costs. One poor-quality retrospective cohort study found those with congestive heart failure who undergo periodontal treatment have lower medical costs than those who do not receive treatment. In terms of health care utilization, 1 poor-quality retrospective cohort study reported periodontal treatment was associated with lower inpatient admissions for those with type 2 diabetes, CAD, or cerebrovascular disease, while another found no significant difference in health care utilization in those with type 2 diabetes who do and do not receive periodontal treatment.

There is some evidence that the balance of benefits and costs of periodontal treatment may differ by individual patient characteristics. For example, in 1 study that reported periodontal treatment was associated with higher medical costs compared to no treatment, authors noted that periodontal treatment was most cost-effective among those with higher HbA1c (who may have more to gain from periodontal treatment-associated improvements in HbA1c) and those who are older (who may have lower lifetime costs of periodontal treatment). Another found savings due to periodontal treatment were limited to those who did not initiate diabetes-related medications after diagnosis.

There are limitations to our rapid review methodology and of our included studies. We used rapid review methods to prioritize synthesis of the best available evidence, rather than all available evidence. These methods included: 1) synthesizing the most recent and relevant SRs, 2) conducting primary study searches to address gaps in the systematic review literature and to identify evidence published after SRs, and 3) having a single reviewer assess study eligibility, study quality, and strength of evidence with second reviewer checking. Common limitations of prioritized SRs included not searching for grey literature, having no publicly available protocol, and lacking discussion of individual studies’ risk of bias. Common limitations of included primary studies were lack of patient and provider blinding in RCTs, and, in controlled observational studies, poorly defined treatment and control groups and the presence of important differences between groups at baseline.
As we primarily found unclear results from studies with methodological limitations, there is a need for better-conducted studies on this topic. Future research should evaluate the effect of periodontal treatment on a broad range of clinically relevant outcomes (including quality of life, diabetes and cardiovascular disease-related complications, and potential harms) measured at shorter (3-6 months) and longer-term (1+ years) time points. VA researchers may additionally wish to use a hybrid effectiveness-implementation study design to evaluate clinically relevant questions around whether referral to dental care improves outcomes.

In conclusion, among people with COPD, periodontal treatment may improve lung function and reduce exacerbations at 1-2 years and reduce annual medical costs. Among people with diabetes or cardiovascular disease, periodontal treatment likely improves some measures of chronic disease severity and inflammation at 3-4 months, but benefits do not appear to persist beyond 6 months. Results are unclear on the relation between periodontal treatment and chronic disease outcomes for those with cerebrovascular disease. Results are also unclear on the relation between periodontal treatment, medical costs, and risk of chronic disease complications among those with diabetes, cardiovascular disease, or cerebrovascular disease.
EVIDENCE BRIEF

INTRODUCTION

PURPOSE

The ESP Coordinating Center (ESP CC) is responding to a request from the Partnered Evidence-Based Policy Resource Center (PEPReC) for an evidence brief on the relation between receipt of preventive dental care and chronic disease-related benefits, harms, and costs. Findings from this evidence brief will be used to inform implementation and evaluation of the Veterans Innovation Center (VIC) Care Coordination for Dental Benefits demonstration program.

BACKGROUND

Poor dental health in the form of periodontal disease is a widespread issue in the United States. Nearly half of US adults aged 30 and older have periodontal disease, and prevalence is highest among older adults (70% of those 65 or older), men (56%), smokers (64%), and those below the federal poverty level (65%).1 While periodontitis and related conditions such as tooth decay compromise oral health and oral quality of life, there is increasing evidence that oral health impacts non-oral chronic diseases such as heart disease, lung disease, stroke, and diabetes. Early evidence of this association was summarized in a 2000 report from United States Surgeon General,2 and in the decades since that report, research on the topic has accelerated.

Most research to date has examined the relation of periodontal disease with cardiovascular disease (CVD) and type 2 diabetes (T2D) outcomes. A 2012 systematic review (SR) by the American Heart Association concluded there is an association between periodontal disease and atherosclerotic vascular disease (ASVD) that is independent of known risk factors.3 In this SR, 18 out of 26 relevant studies reported poor periodontal status was associated with increased risk of ASVD-related outcomes (such as coronary heart disease [CHD], coronary artery disease [CAD], and mortality from ASVD and CHD causes). Eleven out of 14 relevant studies found poor periodontal status was linked with increased risk of stroke. Along the same lines, a 2013 SR by the European Federation of Periodontology and the American Academy of Periodontology found a “small body of evidence [that] supports significant, adverse effects of periodontal disease on glycaemic control, diabetes complications, and development of type 2 (and possibly gestational) diabetes.”4 Additionally, a 2006 SR5 and several subsequent observational studies6,7 have suggested there may be a relation between periodontal disease and respiratory diseases such as chronic obstructive pulmonary disease (COPD).

Periodontal disease (which includes gingivitis and periodontitis) is a gum infection that typically results from poor oral hygiene. Symptoms include bleeding or receding gums in mild cases and painful abscesses and loss of teeth in severe cases.8 Because periodontal disease triggers an inflammatory response in the body, it may contribute to worsening of diseases whose etiology or severity are in part driven by chronic inflammation.4,9 Importantly, however, this pathway is not fully understood and may differ by chronic disease. For instance, it is possible that periodontal disease may cause or worsen some chronic diseases, but it may also be the case that the conditions have 1 or more shared causes, such as smoking, alcohol misuse, overweight/obesity, or socioeconomic factors. For T2D in particular, there is considerable evidence that while
periodontal disease may impact glycemic control, T2D itself likely worsens oral health (periodontal disease has been recently described as the “sixth complication of diabetes”).\(^3,^{10,11}\)

There are several plausible biological mechanisms that may explain the link between periodontal disease and chronic disease outcomes. One possibility is that periodontal disease-related inflammation causes the destruction of endothelial cells that line the walls of blood vessels and maintain normal blood pressure.\(^9\) High blood pressure is a risk factor for development of CVD and cerebrovascular diseases as well as adverse events such as myocardial infarction and stroke.\(^12\) A second potential pathway is that oral bacteria such as *Porphyromonas gingivalis* directly invade arterial walls through the breakdown of gum tissue, causing vascular inflammation and atherosclerosis.\(^9\) For those with COPD, oral bacteria can be inhaled into the lower respiratory tract, which can eventually trigger COPD-related exacerbations.\(^7\) Finally, periodontal disease may trigger production of highly reactive chemical molecules that cause oxidative stress throughout the body.\(^9\) For people with T2D, oxidative stress may contribute to vascular complications such as retinopathy, nephropathy, and cardiomyopathy.\(^13\)

Despite growing evidence linking periodontal disease to chronic disease outcomes, it is unclear whether interventions that have been shown to successfully treat periodontal disease can also lead to clinically meaningful improvement in CVD, T2D, or other chronic disease outcomes. There is a pressing need to address this question given the high comorbidity of chronic diseases among those with, or at risk for, periodontal disease. For example, in a recent case-control study of 1,199 people with periodontal disease, 19% had comorbid hypertension, 9.7% had comorbid endocrine disorders, and 8.5% had comorbid pulmonary disorders.\(^14\) Chronic conditions are especially prevalent among Veterans: it has been estimated that 43% of Veterans have hypertension, 25% have T2D,\(^15,^{16}\) 10% have coronary heart disease,\(^16\) 5% have experienced stroke,\(^16\) and 8% have experienced myocardial infarction.\(^16\) Although the prevalence of COPD among Veterans is unknown, it is thought to be increasing, particularly among Operation Enduring Freedom/Operation Iraqi Freedom Veterans.\(^17\)

Currently, only 8% of Veterans have a dental issue that is service-connected, or meet other criteria required to receive dental care through the Department of Veterans Affairs (VA).\(^18\) To help address this issue, the VA initiated the Veterans Innovation Center (VIC) Care Coordination for Dental Benefits program. This demonstration program is designed to increase Veteran access to dental health care by connecting them with community-based, pro bono, or discounted dental service providers.\(^18\) The goal of the program is to improve Veterans’ health while also decreasing health care-related costs from emergency dental-related care by enabling VA administrative staff to coordinate community-based care for Veterans that are otherwise ineligible to receive dental care at the VA. In 2020, the VA Partnered Evidence-Based Policy Resource Center (PEPReC) was tasked with evaluating the impact of the program on Veterans’ health and health care utilization, and requested a rapid review of the impact of detection and treatment of dental problems on chronic disease outcomes to help inform this evaluation.

Detection and early treatment of dental problems, including periodontal disease, is commonly carried out through the provision of preventive dental services such as routine exams, cleanings, and education on oral hygiene. Regular access to these services may reduce painful and costly dental complications, and conceivably routine dental care and detection of dental problems may positively impact chronic disease outcomes (Figure 1). Consequently, the VA’s demonstration program could impact Veterans’ health beyond reducing dental-related emergency care if it leads
Evidence Brief: Detection and Treatment of Dental Problems

To improved oral health and successful treatment of periodontal disease, and if that treatment results in improvement in chronic disease outcomes. The purpose of the current ESP review is to evaluate whether detection and treatment of dental problems has an impact on chronic disease-related outcomes for those with CVD, cerebrovascular disease, T2D, or COPD. Specifically, we focused on the detection and treatment of periodontal disease, as the link between periodontal disease and chronic disease is well evidenced and represents the area where the VA pilot program could have meaningful clinical impact.

Figure 1. Conceptual Pathway between Receipt of Preventive Dental Services and Improvement in Chronic Disease Outcomes

SCOPE

This rapid review summarizes the benefits and harms of detection and treatment of dental problems on non-dental health, quality of life, health care utilization, and costs among adults with CVD, cerebrovascular disease, T2D, and/or COPD. An analytic framework depicting these key questions and PICOTS is presented in Figure 2.

KEY QUESTIONS

**Key Question 1:** Among adults with CVD, cerebrovascular disease, T2D, and/or COPD, does detection and treatment of dental problems improve patient-reported symptoms and other complications of chronic disease?

**Key Question 2:** Among adults with CVD, cerebrovascular disease, T2D, and/or COPD, does detection and treatment of dental problems improve indicators of chronic disease management (eg, HbA1c, blood pressure, cholesterol) and patient quality of life?

**Key Question 3:** Among adults with CVD, cerebrovascular disease, T2D, and/or COPD, does detection and treatment of dental problems decrease health care utilization and costs?
**Key Question 4:** Among adults with CVD, cerebrovascular disease, T2D, and/or COPD, what are the possible harms of detection and treatment of dental problems?

**ELIGIBILITY CRITERIA**

The ESP included studies that met the following criteria:

- **Population:** Adults (excluding pregnant women) with CVD, cerebrovascular disease, T2D, and/or COPD

- **Intervention:** Detection and treatment of dental problems (*ie*, use of preventive dental services such as regular oral exams, detection of dental problems, and treatment of dental problems detected during exams)

- **Comparator:** No detection or treatment of dental problems

- **Outcomes:**
  - Clinical outcomes (*eg*, patient-reported symptoms, complications of chronic diseases)
  - Chronic disease indicators (*eg*, HbA1c, blood pressure, cholesterol)
  - Quality of life (*eg*, oral health-related quality of life, overall quality of life)
  - Healthcare utilization (*eg*, emergency department visits for non-traumatic dental conditions or non-dental conditions, health care visits associated with chronic disease management, direct costs)
  - Harms (Any)

- **Timing:** Any

- **Setting:** Any

- **Study design:** Using a best-evidence approach, we prioritized evidence from systematic reviews (SRs) and multisite comparative studies that adequately controlled for potential patient-, provider-, and system-level confounding factors. Inferior study designs (*eg*, single-site, inadequate control for confounding, noncomparative) were only included when they filled gaps in higher-level evidence
Figure 2. Analytic Framework of Key Questions and PICOs

Detection & treatment

- Adults with chronic diseases
  - Preventive dental services (ie, cleaning & periodic exam) & detection of dental problems
    - No problems detected
      - No treatment
    - Detected dental problem
      - Treatment

KQ2
- Indicators of chronic disease management
  - Chronic disease indicators (eg, blood pressure, HbA1c, cholesterol)
  - Quality of life

KQ1 & 3
- Clinical outcomes (eg, patient-reported symptoms and complications of chronic diseases)
  - Health care utilization
  - Costs

KQ4
- Harms
METHODS

SEARCHES AND STUDY SELECTION

We conducted a 2-stage search to identify studies addressing our key questions. In the first stage, a research librarian searched Ovid MEDLINE, Cochrane Database of Systematic Reviews (CDSR), and other SR databases for SRs published from database inception to October 2020 using terms for dental care and chronic diseases (ie, CVD, cerebrovascular disease, diabetes, or COPD). In the second stage, the research librarian searched Ovid MEDLINE and CENTRAL from database inception to December 2020 for primary studies of PICOTS not addressed by SRs, and from January 2019 to December 2020 for primary studies published since the end date of the most recent and relevant SRs’ searches.

The first stage of the search identified several SRs on the relation of periodontal treatment to CVD and T2D clinical outcomes. We did not identify any SRs addressing cerebrovascular disease or COPD, non-clinical outcomes (eg, quality of life, health care utilization, or costs) for any chronic disease, or interventions other than periodontal treatment. As a result, 2 gap searches were conducted to identify primary studies examining the relation of periodontal treatment to all outcomes among those with cerebrovascular disease or COPD, and the relation of periodontal treatment to health care utilization, costs, quality of life, complications, and patient-reported symptoms among those with diabetes or CVD. A third search was conducted from January 2019 to Dec 2020 to identify primary studies, published since the end date of the most recent and relevant SRs’ searches, related to periodontal treatment and clinical outcomes for those with diabetes or CVD. Complete search strategies for the SR and primary study searches are described in the Supplementary Materials.

We limited the interventions included in gap searches to periodontal treatment for 2 reasons. First, all SRs identified in the first stage focused on periodontal treatment (and not other interventions, such as dental cleaning or periodic exams). Second, although periodontal disease may affect chronic diseases through several mechanisms, detection and treatment of periodontal disease is the most likely intervention through which dental services may improve chronic disease management and patient quality of life (see Background section and Figure 1). Based on these observations, we limited the review scope to evidence of the direct association between periodontal treatment and chronic disease outcomes.

Additional citations were identified from hand searching reference lists and consultation with content experts. We limited the search to published and indexed articles involving human subjects available in the English language. Study selection was based on the eligibility criteria described above (see Supplementary Materials for full inclusion/exclusion criteria). SRs had to meet 4 criteria established by the AHRQ Evidence-based Practice Program to merit inclusion: 1) have an explicit and adequate search, 2) apply predefined eligibility criteria to select studies, 3) conduct risk of bias assessment for included studies, and 4) present a synthesis of results. All titles, abstracts, and full-text articles were reviewed by 1 investigator and checked by another. All disagreements were resolved by consensus.
QUALITY ASSESSMENT AND DATA EXTRACTION

Given the large number of SRs published on this topic, we used guidance from the AHRQ Evidence-based Practice Center Program\(^{19}\) to prioritize the most recent and relevant SRs to discuss in our review. We then used predefined criteria from AMSTAR-2 to assess the quality of prioritized SRs\(^{20}\) and gave final assessments of high (no or 1 non-critical weakness), moderate (more than 1 non-critical weakness), low (1 critical flaw with or without non-critical weaknesses), or critically low quality (more than 1 critical flaw with or without non-critical weaknesses). We included all primary studies that addressed gaps in evidence from our prioritized SRs. We used Cochrane’s Risk of Bias Tool 2.0 to rate the quality of randomized controlled trials,\(^{21}\) and Cochrane’s ROBINS-I tool to rate the quality of observational studies with control groups, and gave final assessments of high, fair, or low quality.\(^{22}\) For observational studies without control groups or modeling studies, we informally assessed study limitations. We abstracted data from all prioritized SRs and all included primary studies as well as results for each included outcome. All data abstraction and quality ratings were first completed by 1 reviewer then checked by another. All disagreements were resolved by consensus.

STRENGTH OF EVIDENCE ASSESSMENT

We graded the strength of the evidence for categories of outcomes based on the AHRQ Methods Guide for Comparative Effectiveness Reviews.\(^{23}\) This approach incorporates 4 key domains: risk of bias (includes study design and aggregate quality), consistency, directness, and precision of the evidence. It also considers other optional domains that may be relevant for some scenarios, such as a dose-response association, plausible confounding that would decrease the observed effect, strength of association (magnitude of effect), and publication bias. Strength of evidence is graded for each key outcome measure, with ratings ranging from high to insufficient, reflecting our confidence that the evidence represents true intervention effects.

We used the following algorithm to make our assessments. Findings supported by a high-quality SR of multiple RCTs (or these RCTs alone) with consistent findings and either no or only minor methodological limitations of included RCTs were rated as **high** strength of evidence. Findings supported by a moderate- or high-quality SR of multiple RCTs (or these RCTs alone) with consistent findings but some methodological limitations of included RCTs were rated as **moderate** strength of evidence. Findings supported by a moderate- or high-quality SR of multiple RCTs (or these RCTs alone) with inconsistent findings or significant methodological limitations of included RCTs, or findings supported by a single good- or fair-quality RCT or controlled observational study, were rated as **low** strength evidence. Findings supported by a single poor-quality controlled study, uncontrolled studies, or for which no studies were available were rated as **insufficient** strength of evidence.

All strength of evidence ratings were first completed by 1 reviewer then checked by another. All disagreements were resolved by consensus.

SYNTHESIS OF DATA

Available evidence on those with type 2 diabetes and CVD was synthesized narratively due to the inclusion of both SRs and primary research studies. We also synthesized evidence on those with COPD and cerebrovascular disease narratively. Although we identified no SRs on these
conditions, primary studies were highly variable in terms of study designs, outcome measurements, and timing of outcome measurements, which precluded us from synthesizing results quantitatively. Findings of included SRs and primary studies (where applicable) were summarized separately for each chronic disease.

The complete description of our methods can be found on the PROSPERO international prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO/; registration number CRD42020215625).

RESULTS

The literature flow diagram (Figure 3) summarizes the results of the search and study selection processes. Among 520 potentially relevant SR citations and 1,248 potentially relevant primary study citations, we included 46 studies (25 SRs24-48 and 21 primary studies49-69). Of the 25 included SRs, we prioritized 8 that were the most recent and relevant: 2 review of reviews25,30 (1 with meta-analysis), 2 Cochrane SRs38,43 (1 with meta-analysis), and 4 other SRs26,32,37,48 (2 with meta-analysis). The remaining 17 SRs were not prioritized because they were already included in a prioritized review of reviews, their PICOs of interest were otherwise covered by more recent or relevant reviews, or they did not report data on clinically relevant outcomes (see Supplementary Materials for a list of these 17 SRs and specific reasons why each was not prioritized). The 21 primary studies included from our gap search and update search consisted of 8 RCTs,49,50,60,65-69 1 non-randomized controlled trial,56 8 retrospective cohort studies,52,53,55,57,59,61,62,64 1 case-control study,58 2 modeling studies,51,63 and 1 self-controlled case-series.54

We found the largest volume of evidence for people with T2D (6 reviews plus 17 primary studies), followed by CVD (2 reviews plus 5 primary studies), cerebrovascular disease (3 primary studies), and COPD (4 primary studies). Most SRs and primary studies examined non-surgical periodontal treatment (eg, scaling and root planing with or without adjunctive treatments such as antibiotics or oral hygiene instructions) although a few SRs included studies that looked at surgical treatment. Comparators generally consisted of no periodontal treatment, delayed treatment, or less-intensive forms of care (eg, oral health instructions only or community care). Across studies, outcomes relevant to all 4 of our key questions were assessed, including 1) patient-reported symptoms and complications of chronic disease (eg, oral health-related quality of life [OHRQoL], frequency of COPD exacerbations, risk of stroke or myocardial infarction); 2) markers of inflammation and chronic disease severity (eg, HbA1c, fasting blood glucose, cholesterol, triglycerides, IL-6, and CRP); 3) health care utilization and costs (eg, inpatient admissions, medical costs); and 4) harms of periodontal treatment.

In terms of quality assessment, 2 SRs (both Cochrane reviews) were high quality, 4 were moderate quality, 1 was low quality, and 1 was critically low quality. Among moderate-quality reviews, common methodological limitations included lack of grey literature searches, absence of a publicly available review protocol, and failure to discuss individual studies’ risks of bias when interpreting results. Low- and critically low-quality reviews also provided insufficient information on data extraction or quality assessment processes. The quality of primary studies ranged from fair to low-quality. Among RCTs, patients and providers were commonly aware of group assignment (ie, unblinded), half of RCTs did not have a publicly available protocol, and there was a lack of information on cointerventions that may have affected results (ie, tooth
brushing). Among cohort studies and other types of controlled, observational studies, limitations included poorly defined treatment or control groups (ie, it was often unclear if people who did not receive periodontal treatment had periodontal disease or were periodontally healthy), inadequate adjustment for differences between treatment and control groups at baseline, and a high likelihood that measured or unmeasured confounders could have influenced results.

A list of excluded studies and study-level data abstraction and quality assessment for included studies appear in the Supplementary Materials.
LITERATURE FLOW

Figure 3: Literature Flowchart

SR articles identified through database and grey literature searching (n=563)
  MEDLINE=460
  CDSR=97
  Grey literature =6

SR articles remaining after removal of duplicates (n=520)

SR titles/abstracts excluded (n=464)

SR full-text articles assessed for relevance (n=56)

SR full-text articles excluded (n=31)
  - Ineligible population=3
  - Ineligible intervention=2
  - Ineligible study type=18
  - Ineligible publication type=5
  - Outdated or ineligible SR =3

Relevant full-text SRs (n=25)

Primary study gap search (n=1,349)
  MEDLINE=1,266
  CCRCT=83

Primary study title/abstracts assessed for eligibility (n=1,248)

Primary study title/abstracts excluded (n=1,175)

Primary full-text study articles accessed for eligibility (n=73)

Primary full-text study excluded (n=52)
  - Ineligible population =12
  - Ineligible intervention=9
  - Ineligible comparator=11
  - Ineligible outcome=7
  - Ineligible study design=4
  - Ineligible publication type=9

Included articles (n=46)
  Prioritized SRs=8
  Non-prioritized SRs=17
  Primary studies=21
TYPE 2 DIABETES

Overview

Six SRs\(^25,26,30,32,37,43\) provide the best available evidence on the link between periodontal treatment and chronic disease indicators for those with T2D, as well as some limited information on other clinically important outcomes (Table 2). Overall, periodontal treatment was associated with small improvements in HbA1c,\(^25,26,30,43\) fasting blood glucose,\(^25\) triglycerides,\(^32\) total cholesterol,\(^32\) and CRP\(^26\) for those with T2D for up to 4 months compared to no or control treatment; however, improvements in most outcomes did not persist at 6 months. Periodontal treatment was not associated with improvements in LDL or HDL cholesterol at 3 or 6 months\(^32\) compared to no or control treatment in patients with T2D, and had mixed results (ranging from no improvement to small improvement favoring periodontal treatment) on other markers of systemic inflammation compared to no or control treatment.\(^30,43\) One SR looked at diabetes-related complications, quality of life, and cost outcomes, but found no evidence.\(^43\) Data on harms were sparse but suggested that periodontal treatment may be associated with minor adverse events (eg, diarrhea, headaches, and nausea/vomiting).

Seventeen primary studies\(^50-53,55,57-59,61-69\) (6 RCTs, 8 retrospective cohort, 1 case-control, and 2 modeling studies) address gaps in SRs or update evidence from SRs (Table 2). Overall, 5 RCTs provided updated data on chronic disease indicators and were generally in agreement with findings from SRs. The remaining 12 studies (1 RCT, 8 retrospective cohort, 1 case-control, and 2 modeling studies) examined outcomes not covered by SRs and generally had unclear results, with some studies reporting periodontal treatment is associated with improvements in oral health-related quality of life (OHRQoL),\(^58\) decreased medical costs,\(^51,57,59,52\) and decreased risk of stroke and myocardial infarction, while others reported no improvements in OHRQoL,\(^50\) increased or no change in medical costs,\(^51,59\) and no significant difference in stroke or myocardial infarction risk compared to no treatment. A single retrospective cohort study\(^53\) reported periodontal treatment is associated with reduced risk of heart failure compared to no treatment. Two studies had conflicting results on health care utilization, with one\(^57\) finding periodontal treatment was associated with lower rates of inpatient admissions for those who received periodontal treatment compared to no treatment, and another\(^61\) finding no significant difference in health care utilization between groups. Finally, a simulation study\(^63\) projected that expanding periodontal treatment coverage would lead to lower risk of diabetes-related complications.

Patient-reported Symptoms and Complications

A high-quality Cochrane review\(^43\) found no studies that reported on diabetes-related complications or quality of life. No other SRs examined this outcome.
Table 2. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With T2 Diabetes

<table>
<thead>
<tr>
<th>Outcome category</th>
<th>Outcome</th>
<th>Results</th>
<th>Supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ1: Patient-reported outcomes and complications</td>
<td>Quality of life</td>
<td>Mixed results (ranging from no statistically significant difference in OHRQoL or diabetes treatment-related QoL between groups at 3 months to better OHRQoL in periodontal tx group [6.05 vs 9.02 on the Oral Health Impact Profile-14; p&lt;.05] at unclear timing among those with HbA1c ≥ 7%)</td>
<td>2 fair-quality RCTs&lt;sup&gt;50,60&lt;/sup&gt; and 1 fair-quality case-control study&lt;sup&gt;28&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Functionality</td>
<td>No statistically significant difference in SF-36 between groups at 3 months</td>
<td>1 fair-quality case-control study&lt;sup&gt;28&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>Mixed results (ranging from ↓ MI incidence in periodontal tx vs no tx group [HR = 0.92, 95% CI (0.85, 0.99)] over max of 3 yrs to no projected difference in annual incidence of MI between groups)</td>
<td>1 fair-quality retrospective cohort study&lt;sup&gt;53&lt;/sup&gt; and 1 computer-based simulation model study&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
<td>↓ Heart failure incidence in periodontal tx vs no tx group (HR = 0.60, 95% CI [0.45, 0.80]) over max of 3 yrs</td>
<td>1 fair-quality retrospective cohort study&lt;sup&gt;53&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Stroke</td>
<td>Mixed results (ranging from no projected or measured difference in stroke incidence over max of 3 yrs groups to ↓ rates of stroke in periodontal tx vs no tx group [0.88%/yr vs 1.08%/yr; p&lt;.001] over max of 10 yrs)</td>
<td>1 fair-quality retrospective cohort study&lt;sup&gt;53&lt;/sup&gt; and 1 poor-quality retrospective cohort study&lt;sup&gt;55&lt;/sup&gt; and 1 computer-based simulation model study&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>CVD events</td>
<td>Expanded periodontal coverage projected to be associated with 7.3% (95% CI [-20.3 to -0.3%]) reduction in annual incidence of CVD events</td>
<td>1 computer-based simulation model study&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Diabetes-related complications</td>
<td>Expanded periodontal coverage projected to be associated with 20.5% (95% CI [-31.2, -9.1%]) reduced nephropathy incidence, 17.7% (95% CI [-32.7, -4.7%]) reduced neuropathy incidence, and 18.4% (95% CI [-34.5, -3.5%]) reduced retinopathy incidence</td>
<td>1 computer-based simulation model study&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
<tr>
<td>KQ2: Chronic disease indicators</td>
<td>HbA1c</td>
<td>↓ HbA1c (MD = -0.32%, 95% CI [-0.5, -0.15%] in periodontal tx vs no tx group at 3-6 months in 1 SR</td>
<td>1 moderate-quality review of reviews&lt;sup&gt;25&lt;/sup&gt; and 1 high-quality Cochrane review&lt;sup&gt;43&lt;/sup&gt; and 5 fair-quality RCTs&lt;sup&gt;65-69&lt;/sup&gt; published after reviews</td>
</tr>
<tr>
<td></td>
<td></td>
<td>↓ HbA1c (WMD = -0.29%, 95% CI [-0.48, 0.10%]) in periodontal tx vs no or control tx group at 3-4 months, no difference between groups at 6 months in the other SR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Similar findings in ↓ HbA1c in 5 newer RCTs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FBG</td>
<td>↓ FBG (WMD = -11.59 mg/dl, 95% CI [-15.2, -8.0]) in periodontal tx vs no tx group at 3-6 months</td>
<td>1 moderate-quality review of reviews&lt;sup&gt;25&lt;/sup&gt; and 1 RCT&lt;sup&gt;65&lt;/sup&gt; published after review of reviews</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Similar findings in ↓ FBG in 1 newer RCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PPG</td>
<td>↓ PPG by 13.28 mg/dL in periodontal tx alone vs no tx group at 3 months (p&gt;.01)</td>
<td>1 fair-quality RCT&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
### Total cholesterol

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>1 moderate-quality SR$^{32}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ Total cholesterol (MD = -0.47 mmol/L, 95% CI [-0.75, -0.18]) in periodontal tx vs no or control tx group at 3 months; no difference at 6 months</td>
<td>1 moderate-quality SR$^{32}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Triglycerides

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>1 moderate-quality SR$^{32}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ Triglycerides (MD = -0.2 mmol/L, 95% CI [-0.24, -0.16]) in periodontal tx vs no or control tx group at 3 months; no difference at 6 months</td>
<td>1 moderate-quality SR$^{32}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### HDL

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>1 moderate-quality SR$^{32}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ HDL (MD = 0.06 mmol/L, 95% CI [.03, .08]) in periodontal tx vs no or control tx group at 3 months; no difference at 6 months</td>
<td>1 moderate-quality SR$^{32}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### LDL

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>1 moderate-quality SR$^{32}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>No statistically significant difference between groups at 3 or 6 months</td>
<td>1 moderate-quality SR$^{32}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CRP

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>1 moderate-quality SR$^{32}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ CRP (Difference in mean changes scores = 1.89 mg/L, 95% CI [1.70, 2.08]) from baseline in periodontal tx vs no tx group at 3-6 months in 1 SR</td>
<td>1 moderate-quality SR$^{32}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### IL-6

<table>
<thead>
<tr>
<th>Systemic inflammation</th>
<th>Studies had mixed findings ranging from no improvement to small improvement favoring periodontal tx</th>
<th>1 low-quality review$^{37}$ and 1 RCT published after review$^{68}$</th>
</tr>
</thead>
</table>

### Cardiac indicators

<table>
<thead>
<tr>
<th>Oxidative stress</th>
<th>Periodontal tx reduced the mean $E/e'$ ratio by 1.66 (95% CI: -2.64, -0.68, p&lt;.01) compared to no tx at 6 months. Left ventricle mass index (LVMI) and NT-proBNP were not significantly improved in tx vs no tx at 6 months.</th>
<th>1 critically low-quality review of reviews$^{30}$ and 1 RCT published after review$^{65}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved oxidative index in periodontal tx vs no tx at 3 months (-1.19, 95% CI [-2.03, -.35]).</td>
<td>1 fair-quality RCT$^{68}$</td>
<td></td>
</tr>
</tbody>
</table>

### KQ3: Health care utilization and costs

<table>
<thead>
<tr>
<th>Costs</th>
<th>Mixed results on costs associated with periodontal tx vs no tx (ranging from higher, to lower, to no difference in costs)</th>
<th>2 fair-quality retrospective cohort studies$^{52,59}$ and 4 poor-quality retrospective cohort studies$^{57,61,62,64}$ and 2 modeling studies$^{51,63}$</th>
</tr>
</thead>
</table>

### Health care utilization

<table>
<thead>
<tr>
<th></th>
<th>Mixed results (ranging from lower rates of inpatient admissions in periodontal tx vs no tx group [40.4 vs. 66.6 inpatient admissions/1,000 subjects/year; p&lt;.05] vs no significant differences between groups in total outpatient physician visits, probability of a hospitalization, or the occurrence of an emergency room visit)</th>
<th>2 poor-quality retrospective cohort studies$^{57,61}$</th>
</tr>
</thead>
</table>

### KQ4: Harms

<table>
<thead>
<tr>
<th>Harms</th>
<th>Some minor adverse events (diarrhea, headaches, and nausea) in both groups; some minor adverse events from doxycycline or chlorhexidine (diarrhea, pain, nausea, taste change, tooth stain) in some studies; otherwise; or no adverse events in periodontal tx group over max of 6 months.</th>
<th>1 high-quality Cochrane review$^{43}$ and 1 moderate-quality review$^{26}$ and 2 RCTs published after reviews$^{66,69}$</th>
</tr>
</thead>
</table>

All results represent differences between periodontal treatment and no treatment groups at follow-up unless otherwise specified.

Key: QoL=Quality of life, OHRQoL=Oral health-related quality of life, Tx=Treatment SF-36=Short Form 36 Health Survey Questionnaire, MI=Myocardial infarction, Yrs=Years, HR=Hazard ratio, CVD=Cardiovascular disease, CI=Confidence interval, WMD=Weighted mean difference, SR=Systematic review, RCT=Randomized controlled trial, FBG=Fasting blood glucose, PPG=, MD=Mean difference, HDL=High density lipoprotein, CRP=C-reactive protein, LDL=Low density lipoprotein
A fair-quality RCT\textsuperscript{50} found that among those with T2D, there were no significant differences in OHRQoL (measured by the General Oral Health Assessment) between periodontal treatment and no treatment at 3 months, and another\textsuperscript{69} found no difference in diabetes treatment-related QoL between groups at 3 months. By contrast, a fair-quality case-control study\textsuperscript{58} found that patients with poorly-controlled T2D (HbA1c ≥ 7\%) who received periodontal treatment had better OHRQoL compared to those who did not receive treatment (6.05 vs 9.02 on the Oral Health Impact Profile-14; p<.05). However, among those with well-controlled diabetes (HbA1c < 7\%), there was no significant difference between groups. A major limitation of this study is that it was unclear what type of periodontal treatment patients received or how long after receiving treatment outcomes were measured. There was also no significant difference between groups on measures of functionality (SF-36) for any patients in the RCT.\textsuperscript{50}

In terms of complications, a fair-quality retrospective cohort study\textsuperscript{53} found that advanced periodontal treatment was associated with a reduction in the rates of myocardial infarction (hazard ratio [HR] = 0.92, 95\% CI [0.85, 0.99]) and heart failure (HR = 0.60, 95\% CI [0.45, 0.80]) but not stroke (HR = 0.95, 95\% CI [0.85, 1.06]) compared to non-advanced periodontal treatment over a maximum follow-up of 3 years. By contrast, a poor-quality retrospective cohort study\textsuperscript{55} found that among those with diabetes mellitus and periodontal disease, the stroke incidence rate was significantly lower in the intensive treatment (.88%/yr) than the no treatment group (1.08%/yr) over a maximum follow-up of 10 years (p<.001). A study\textsuperscript{63} that used a computer-based simulation model to project reductions of complications when periodontal treatment coverage is expanded among those with T2 diabetes (from 28\% to 88\% coverage) found expanded periodontal treatment coverage was associated with 7.3\% reduced nephropathy incidence (95\% CI [-20.3, -0.3]), 17.7\% reduced neuropathy incidence (95\% CI [-32.7, -4.7%]), and 18.4\% reduced retinopathy incidence (95\% CI [-34.5, -3.5%]) among those with T2 diabetes. Stroke and myocardial infarction incidence were also projected to be reduced by 5\% (95\% CI [-20.8, 3.9\%]) but the difference was not statistically significant.

Overall, findings on the relation between periodontal treatment and patient-reported symptoms and complications for those with T2D are supported by low strength of evidence, as results were inconsistent across studies and studies were primarily observational with important methodological limitations. Additionally, results from the simulation study should be interpreted with caution because they were projected using a mathematical model that required the authors to make a number of assumptions about the link between periodontal treatment and diabetes-related complications that have not been directly evaluated.

**Chronic Disease Indicators**

A moderate-quality review of reviews\textsuperscript{25} found periodontal treatment was associated with a small but significant improvement in mean HbA1c levels at 3-6 months when compared to no treatment (weighted mean difference [WMD] = -0.32\%, 95\% CI [-0.5, -0.15]). A high-quality Cochrane review\textsuperscript{43} of RCTs found similar results for HbA1c at 3-4 months (MD = -0.29\%, 95\% CI [-0.48, -0.10]) but noted mean HbA1c levels were no longer significantly different between groups at 6 months. The review of reviews\textsuperscript{25} also reported periodontal treatment was associated with improvements in fasting blood glucose at 3-6 months when compared to no treatment (WMD = -11.59 ml/dl, 95\% CI [-15.2, -8.0]), but did not evaluate whether outcomes differed at 3 or 6 months. Five RCTs\textsuperscript{65-69} published after these SRs found similar results for HbA1c.
Periodontal treatment was also associated with shorter-term improvements in total cholesterol, triglycerides, and CRP levels when compared to no or control treatment. A moderate-quality review\(^3\) reported periodontal treatment was associated with improvements in total cholesterol (mean difference [MD] = -0.47 mmol/L, 95% CI [-0.75, -0.18]) and triglycerides (MD = -0.2 mmol/L, 95% CI [-0.24, -0.16]) levels compared to no or control treatment, while the control arm was associated with improvements in HDL cholesterol (MD = 0.06 mmol/L, 95% CI [0.03, 0.08]) levels compared to periodontal treatment, all at 3 months. However, the review found no significant differences between groups at 6 months. Another moderate-quality review\(^2\) found a significant reduction in mean CRP level from baseline among those receiving periodontal treatment compared to no treatment (difference in mean change scores = 1.89 mg/L, 95% CI [1.70, 2.08]) at 3-6 months. This SR did not evaluate whether outcomes differed at 3 or 6 months. However, an RCT\(^6\) published after this SR found no significant improvements in CRP between the treatment and no treatment groups at 6 months. Individual, fair-quality RCTs additionally found periodontal treatment was associated with significantly better post-prandial glucose (PPG) at 3 months, improvements in oxidative stress at 3 months, and improvement in some measures of cardiac health (E/e’ ratio) but not others (left ventricle mass index and NT-proBNP) at 6 months compared to no treatment.

Finally, a moderate-quality review\(^3\) found no significant differences in mean LDL cholesterol levels between periodontal treatment and no treatment or control treatment groups at 3 or 6 months. A low-quality review\(^7\) reported that 7 studies found periodontal treatment was associated with improvements in mean IL-6 levels, while 9 studies did not find any impact (follow-up time not reported). An RCT\(^6\) published since the review found no significant difference in IL-6 between periodontal treatment and no treatment at 6 months. Finally, a critically low-quality review of reviews\(^8\) found mixed results on the relation of periodontal therapy to measures of systematic inflammation (follow-up time not reported).

Overall, findings on the relation between periodontal treatment and chronic disease indicators for those with T2D are supported by moderate strength of evidence. Although we identified several moderate- and high-quality SRs of RCTs examining these outcomes, SR authors noted that the RCTs that composed the reviews had some methodological limitations including a lack of masking of participants and study personnel as well as incomplete outcome data.

### Health Care Utilization and Costs

A high-quality Cochrane review\(^4\) found no studies that reported data on costs. No other SRs examined this outcome, and no SRs examined health care utilization. Findings on costs from primary studies of primarily insurance claims data have mixed results, with studies indicating that periodontal treatment was associated with higher, lower, and no significant differences in costs compared to no periodontal treatment.

First, 5 studies\(^5\) found periodontal treatment was associated with lower costs compared to no treatment. A fair-quality retrospective cohort study\(^5\) conducted in the Netherlands found a small reduction in diabetes-related health care costs per quarter per year (-€12.03, 95% CI [-15.77, -8.29]) following periodontal treatment compared with no periodontal treatment. Several additional, poor-quality retrospective studies\(^5\) based on claims data found similar results. One of these was a US-based retrospective cohort study\(^5\) that found that, among those with newly diagnosed T2D, periodontal treatment was associated with lower healthcare costs.
compared to no treatment ($1,799 lower over 2 years, p=.01), although benefits were limited to those who did not initiate diabetes medications after diagnosis. Another was a US-based retrospective cohort study\textsuperscript{62} that found that people with T2D who received periodontal care had $1,750 lower annual medical costs than those who did not (statistical significance not evaluated). A third was a retrospective cohort study\textsuperscript{57} based in the US which found that those with T2D who received periodontal treatment had significantly lower mean annual medical costs than those who did not receive treatment ($4,216 vs $7,056; p<.04). A final study\textsuperscript{63} that used a computer-based simulation model to project costs of expanding periodontal treatment coverage among those with T2D (from 28\% to 88\% coverage) found that expanded coverage was associated with savings of $5,904 (95\% CI [-6,039, -5,769]) per capita.

By contrast, 2 studies\textsuperscript{51,59} found periodontal treatment was associated with higher costs compared to no treatment. A fair-quality, retrospective cohort study based on claims data\textsuperscript{59} conducted in the US found that after adjusting for disease burden, those with diabetes mellitus who received periodontitis or gingivitis treatment had higher per-member per-year medical costs than those who received other dental services or no dental services (adjusted costs not reported). This finding was echoed by a second modeling study\textsuperscript{51} conducted in the UK that found medical costs for people with T2D who received periodontal treatment was higher than those that did not receive treatment (incremental costs ranged from £504 to £1,056). Authors pointed out that the intervention was most cost-effective for those who are older and who have higher HbA1c. A final, poor-quality retrospective cohort study\textsuperscript{64} found no significant differences in medical costs for those with newly diagnosed T2D who undergo periodontal treatment versus those who do not.

Studies also had unclear results in terms of health care utilization. One poor-quality retrospective cohort study\textsuperscript{57} found that receipt of periodontal treatment was associated with lower rates of inpatient admissions compared to controls (40.4 vs 66.6 inpatient admissions/1,000 subjects/year; p<.05), while another\textsuperscript{61} found no significant difference between groups in number of outpatient physician visits, probability of hospitalization, or occurrence of an emergency room visits.

These studies had major limitations which reduce our certainty in the findings. First, for most studies based on claims data, it was unclear whether people in the control group who did not receive periodontal treatment had periodontal disease or were periodontally healthy. It is therefore possible that confounders associated with periodontal disease – rather than periodontal treatment itself – influenced the results. One study\textsuperscript{57} attempted to control for periodontal disease status by including people who had received 1, 2, or 3 sessions of periodontal treatment in the control group (compared to 4 sessions in the intervention group). Consequently, study groups may actually represent levels of adherence to treatment rather than a comparison between receipt versus no receipt of treatment. A second limitation of the studies of claims data is that most only evaluated data from participants who were continually enrolled in both medical and dental insurance and who were alive for the duration of the study. Authors of 1 study\textsuperscript{64} commented that this may have excluded younger patients (who may have changed their health insurance) and older patients (who may have died during the study). Authors of another study\textsuperscript{61} explicitly stated that selection bias could have influenced their results, given that limiting participants to those continually enrolled in insurance reduced the sample size to around 15\% of the total sample.
Overall, findings on the relation between periodontal treatment and health care utilization and costs for those with T2D are supported by low strength of evidence, because results were inconsistent across studies and studies were primarily observational with important methodological limitations.

**Harms**

A high-quality Cochrane review found that most of its included studies (20/35) did not report on adverse events, and several others (11/35) reported that either no adverse events or no major adverse events occurred. Of the remaining 4 studies, 1 study reported no adverse events occurred from use of doxycycline and 3 studies reported minor adverse events due to treatment in both groups (including diarrhea, headaches, nausea/vomiting) or due to doxycycline or chlorhexidine (including diarrhea, pain, nausea, taste change, and tooth stain). None of the included studies in another moderate-quality review reported on the occurrence of adverse effects or complications of periodontal treatment. Two fair-quality RCTs published since these reviews also reported there were no harms of periodontal treatment. Overall, findings on the relation between periodontal treatment and harms for those with T2D are supported by moderate strength of evidence. Importantly, although evidence is available on harms from a high-quality SR and 2 additional fair-quality RCTs, only half the studies in the included SR reported on this outcome.

**CARDIOVASCULAR DISEASE**

**Overview**

Two SRs provide the best available evidence on the link between periodontal treatment and chronic disease indicators among those CVD (Table 3). Overall, for those which chronic heart disease, periodontal treatment was associated with improvements in TNF-α, IL-6 and CRP at 3 months compared to no treatment. For those with hyperlipidemia, periodontal treatment was also associated with improvements in LDL and CRP at 3 months compared to no treatment. Although additional clinically relevant outcomes (ie, all-cause and CVD-related mortality, cardiovascular events, and adverse events) were examined by 1 review, authors did not find sufficient data to draw conclusions.

Four primary studies (4 retrospective cohort and 1 self-controlled case series) addressed gaps in SR evidence by examining the association between periodontal treatment and cardiovascular events, health care utilization, and costs (Table 3). Overall, data on complications of CVD are unclear. One retrospective cohort study indicated those with hypertension and atherosclerosis who received periodontal treatment had a lower risk of stroke than those who did not receive treatment, while a self-controlled case series indicated the risk of myocardial infarction increased in the 4 weeks after intensive dental treatment compared to baseline then decreased over the next 20 weeks. Results on costs are also unclear, with 1 retrospective cohort study indicating those with coronary artery disease (CAD) had higher per-member per-month medical costs than those who did not receive treatment and 2 others indicating those with CAD had lower annual medical costs. One of these studies reported those with CHD similarly had lower annual medical costs than those who did not receive treatment, and the other reported lower inpatient admissions among those with CAD who received treatment. No SRs or primary studies reported on harms.
Patient-reported Symptoms and Complications

A high-quality Cochrane review\(^3\) looked for data on all-cause and CVD-related mortality and cardiovascular events but found only a single relevant study with high attrition. A poor-quality, retrospective cohort study\(^5\) identified in the gap search found that among those with periodontal disease and hypertension, the stroke incident rate was lower in the intensive treatment group (.83%/yr) than in the no treatment group (1.09%/yr) over a maximum follow-up of 10 years (p<.001). This study found similar results for those with atherosclerosis (incident rate of intensive treatment = 1.00%/yr vs IR of no treatment = 1.18%/yr; p<.001). A self-controlled case-series\(^5\) reported the rate of myocardial infarction was higher in the first 4 weeks after an invasive dental treatment compared with baseline (incident ratio [IR] = 1.56, 95% CI [0.98, 2.47]), but noted that this rate decreased over the subsequent 20 weeks. Overall, findings on the relation between periodontal treatment and patient-reported symptoms and complications for those with CVD are supported by insufficient strength of evidence, as studies reported conflicting results and either were poor quality or did not have a separate control group.

Chronic Disease Indicators

A moderate-quality review\(^4\) included 3 studies of periodontal treatment compared to no treatment for those with CVD. One study found those with chronic heart disease who received periodontal treatment experienced improvements in TNF-\(\alpha\), IL-6, and CRP levels at 3 months compared to no treatment. The second found that those with refractory hypertension who received periodontal treatment experienced improvements in IL-6 and CRP levels at 6 months, although it is unclear whether control groups also improved. The final study found that those with hyperlipidemia who received periodontal treatment experienced improvements in LDL and CRP levels compared to no treatment at 3 months. By contrast, a high-quality Cochrane review\(^3\) looked for data on blood test results for those with CVD undergoing periodontal treatment but found no usable data due to substantial attrition in the single relevant study. Overall, findings on the relation between periodontal treatment and chronic disease indicators for those with CVD are supported by low strength of evidence. Although findings are supported by a high- and a moderate-quality SR, the SRs came to different conclusions based on the small number of available studies that had important methodological limitations including high attrition.
Table 3. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Cardiovascular Disease

<table>
<thead>
<tr>
<th>Outcome category</th>
<th>Outcome</th>
<th>Results</th>
<th>Supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ1: Patient-reported outcomes and complications</td>
<td>CVD events</td>
<td>No usable data due to high attrition in the single relevant study.</td>
<td>1 high-quality Cochrane review&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>All-cause and CVD-related mortality</td>
<td>No data found</td>
<td>1 high-quality Cochrane review&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Stroke</td>
<td>People with hypertension: lower stroke rates in periodontal tx vs no tx group (0.83%/yr vs 1.09%/yr; p&lt;.001) over max of 10 yrs</td>
<td>1 poor-quality, retrospective cohort study&lt;sup&gt;55&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>People with atherosclerosis: lower stroke rates in periodontal tx vs no tx (1.00%/yr vs 1.18%/yr; p&lt;.001) over max of 10 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MI</td>
<td>MI incidence higher in 4 weeks after invasive dental treatment vs baseline (IR = 1.56, 95% CI [0.98, 2.47])</td>
<td>1 self-controlled case-series&lt;sup&gt;54&lt;/sup&gt;</td>
</tr>
<tr>
<td>KQ2: Chronic disease indicators</td>
<td>TNF-α</td>
<td>People with CHD: improved at 3 months in periodontal tx vs no tx group</td>
<td>1 moderate-quality review&lt;sup&gt;48&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>People with CHD: improved at 3 months in periodontal tx vs no tx group</td>
<td>1 moderate-quality review&lt;sup&gt;48&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>CRP</td>
<td>People with CHD or hyperlipidemia: improved at 3 months in periodontal tx vs no tx group</td>
<td>1 moderate-quality review&lt;sup&gt;48&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>LDL</td>
<td>People with hyperlipidemia: improved at 3 months in periodontal tx vs no tx group</td>
<td>1 moderate-quality review&lt;sup&gt;48&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Blood tests</td>
<td>No usable data due to high attrition in the single relevant study.</td>
<td>1 high-quality Cochrane review&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td>KQ3: Healthcare utilization and costs</td>
<td>Costs</td>
<td>People with CAD: mixed results (ranging from higher to lower costs)</td>
<td>1 fair-quality&lt;sup&gt;59&lt;/sup&gt; and 2 poor-quality&lt;sup&gt;52,57&lt;/sup&gt; retrospective cohort studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>People with CHD: periodontal tx associated with lower costs than no tx</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inpatient admissions</td>
<td>People with CAD: lower rates of inpatient admissions in periodontal tx vs no tx group (46.6 vs 65.2 inpatient admissions/1,000 subjects/year; p&lt;.01)</td>
<td>1 poor-quality retrospective cohort study&lt;sup&gt;57&lt;/sup&gt;</td>
</tr>
<tr>
<td>KQ4: Harms</td>
<td>Harms</td>
<td>No usable data due to high attrition in the single relevant study.</td>
<td>1 high-quality Cochrane review&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

All results represent differences between periodontal treatment and no treatment groups at follow-up unless otherwise specified.

Key: CVD=Cardiovascular disease, Tx=Treatment, Yrs=Years, MI=Myocardial infarction, IR=Incidence ratio, CHD=Coronary heart disease, CRP=C-reactive protein, LDL=Low density lipoprotein, CAD=Coronary artery disease
Health Care Utilization and Costs

A poor-quality retrospective cohort study reported that receipt of periodontal treatment was associated with significantly lower rates of inpatient admissions compared to no treatment among people with coronary artery disease (CAD) (46.6 vs 65.2 inpatient admissions/1,000 subjects/year; p<.01). As noted above, a major limitation of this study was that the control group was active (control participants received 1, 2, or 3 sessions of periodontal treatment compared to 4 sessions in the intervention group), which could have attenuated observed treatment effects.

In terms of costs, a fair-quality retrospective cohort study reported that after adjusting for disease burden, people with CAD who received periodontal treatment incurred higher per-member per-month medical costs than those who received no dental services (adjusted costs not reported). By contrast, a poor-quality retrospective cohort study found that those with CAD who received periodontal treatment had significantly lower annual medical costs than those who did not receive treatment ($9,133 vs $10,222; p<.04). A second poor-quality retrospective cohort study conducted in the US found that people with CAD who received periodontal treatment had lower annual medical costs compared to those who did not receive periodontal treatment (average $15,549-$16,271 in periodontal treatment group vs $20,502-$21,202 in no treatment group depending on compliance with medical care). Authors noted similar results for those with congestive heart disease (average $35,669-$36,172 in periodontal treatment group vs $47,332-$49,064 in no treatment group depending on compliance with medical care). Differences were not evaluated for statistical significance in this study, which was published as a report by United Healthcare.

Overall, findings on the relation between periodontal treatment and healthcare utilization and costs for those with CVD are supported by low strength of evidence, as studies reported conflicting results and were all observational with important methodological limitations.

Harms

A high-quality Cochrane review looked for data on harms but found no usable data due to high attrition in the single relevant study. No primary studies identified in the gap search reported on harms.
CEREBROVASCULAR DISEASE

Overview

We did not identify any SRs examining the link between periodontal treatment and any outcomes of interest for those with cerebrovascular disease. Three primary studies\textsuperscript{54,57,59} (2 retrospective cohort and 1 self-controlled case series) conducted in those with cerebrovascular disease reported similar findings as those with CVD (Table 4). One retrospective cohort study\textsuperscript{59} found that after adjusting for disease burden, people with cerebrovascular disease who underwent periodontal treatment had higher medical costs than those who did not receive dental services, while another\textsuperscript{57} found they have lower annual medical costs and lower rates of inpatient admissions. A third self-controlled case series\textsuperscript{54} found that the risk of ischemic stroke was higher in the 4 weeks after intensive dental therapy than at baseline.

Patient-reported Symptoms and Complications

A self-controlled case series\textsuperscript{54} reported that the risk of stroke was slightly elevated in the 4 weeks after an invasive dental treatment (IR = 1.39, 95% CI [0.89, 2.15]) with an unclear pattern of resolution in the following weeks. Overall, this finding is supported by insufficient strength of evidence as the single observational study did not have a separate control group.

Chronic Disease Indicators

No studies reported on chronic disease indicators.

Health Care Utilization and Costs

One fair-quality retrospective cohort study\textsuperscript{59} found that after adjusting for disease burden, people with cerebrovascular disease who underwent periodontal treatment had higher medical costs than those who did not receive dental services (adjusted costs not reported). By contrast, a poor-quality retrospective cohort study\textsuperscript{57} indicated people with cerebrovascular disease who received periodontal treatment had lower mean annual medical costs compared to those who did not receive dental services ($8,214 vs $13,895; p<.04). This study also reported lower rates of inpatient admissions in the periodontal treatment group compared to the no treatment group (350.0 vs 444.4 inpatient admissions/1,000 subjects/year; p<.002). Overall, findings are supported by low strength of evidence, as studies reported conflicting results and were observational with important methodological limitations, including 1 study whose comparison group was composed of those who received 1, 2, or 3 sessions of periodontal therapy and another whose comparison group was composed of people who may have been periodontally healthy.

Harms

No primary studies reported on harms.
Table 4. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Cerebrovascular Disease

<table>
<thead>
<tr>
<th>Outcome category</th>
<th>Outcome</th>
<th>Results</th>
<th>Supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ1: Patient-reported outcomes and complications</td>
<td>Stroke</td>
<td>Risk of stroke is higher in 4 weeks after invasive dental treatment vs baseline (IR = 1.39, 95% CI [0.89, 2.15])</td>
<td>1 self-controlled case series54</td>
</tr>
<tr>
<td></td>
<td>Costs</td>
<td>Mixed results (ranging from higher to lower costs in periodontal tx group)</td>
<td>1 fair-quality59 and 1 poor quality57 retrospective cohort study</td>
</tr>
<tr>
<td></td>
<td>Inpatient admissions</td>
<td>Lower inpatient admission rates in periodontal tx group vs no tx group (350.0 vs. 444.4 inpatient admissions/1,000 subjects/yr; p&lt;.002)</td>
<td>1 poor-quality retrospective cohort study57</td>
</tr>
</tbody>
</table>

All results represent differences between periodontal treatment and no treatment groups at follow-up unless otherwise specified.

Key: IR=Incidence ratio; CI=Confidence interval; Tx=Treatment; Yr=Year

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Overview

We did not identify any SRs examining the link between periodontal treatment and any outcomes of interest for those with COPD. Four primary studies49,56,60 (2 RCTs, 1 non-randomized, controlled trial, and 1 retrospective cohort study) examined outcomes of periodontal treatment versus no treatment among people with COPD (Table 5). One RCT49 and 1 non-randomized controlled trial56 found that periodontal treatment was associated with reductions in the frequency of COPD exacerbations at 1 and 2 years, while another, shorter RCT60 indicated that periodontal treatment had no significant effect on COPD-related quality of life, self-assessment of health, or illness severity at 1 month. This RCT60 also found a reduction in doctor visits in both treatment and control groups (significance not assessed) and no adverse events in either group. The retrospective cohort study62 found lower annual medical costs among those who received periodontal treatment compared to those who did not.

Patient-reported Symptoms and Complications

A fair-quality RCT49 (N=60) and another fair-quality, non-randomized controlled trial56 (N=40) found that periodontal treatment was associated with significant reductions in the mean frequency of COPD exacerbations at 1 year (1.95 vs 3.25 exacerbations/patient-year) and 2 years (30% of patients experiencing frequent/70% experiencing infrequent exacerbations vs 66.7% frequent/33.3% infrequent) compared to no treatment. A shorter and smaller fair-quality RCT60 (N=30) did not find significant differences between treatment groups in COPD-related quality of life (measured by SGRQ-A), self-assessment of health, or illness severity at 1 month. These findings are supported by low strength of evidence, as evidence on short- and long-term findings conflict, and RCTs were small with important methodological limitations including 1 study that did not describe how patients were allocated to treatment versus control groups.
**Chronic Disease Indicators**

A fair-quality RCT\(^49\) (N=60) with 2 periodontal treatment groups (scaling and root planing or supragingival scaling treatment) found both forms of treatment had a significant, positive effect on measures of lung function (including forced expiratory volume in the first second [FEV1] and forced vital capacity [FEV1/FVC]) compared with no treatment at 2 years. These findings are supported by low strength of evidence, as evidence comes from a single, small RCT that did not mask participants and had no publicly available protocol.

**Health Care Utilization, Costs, and Harms**

A fair-quality RCT\(^60\) (N=30) found a reduction in doctor visits in both treatment and control groups and no adverse events in either group at 1 month. A poor-quality retrospective cohort study\(^62\) found that those with COPD who received periodontal treatment had lower annual medical costs than those who did not receive treatment ($12,938-$38,450 vs $15,817-$52,484 depending on medical compliance). These findings are supported by low strength of evidence, as evidence comes from a single, small RCT that did not mask participants and had no publicly available protocol, as well as a retrospective cohort study that did not clearly report whether people in the no treatment group had periodontal disease or were periodontally healthy.

**Table 5. Overview of Best Available Evidence on Periodontal Treatment vs No Treatment Among Adults With Chronic Obstructive Pulmonary Disease**

<table>
<thead>
<tr>
<th>Outcome category</th>
<th>Outcome</th>
<th>Results</th>
<th>Supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ1: Patient-reported outcomes and complications</td>
<td>COPD exacerbations</td>
<td>Lower rates of exacerbations in periodontal tx vs no tx group at 1 yr (1.95 vs 3.25 exacerbations/ patient-year) and 2 yrs (30% experienced frequent/70% infrequent exacerbations vs 66.7% frequent/33.3% infrequent)</td>
<td>1 fair-quality RCT(^49) and 1 non-randomized controlled trial(^56)</td>
</tr>
<tr>
<td></td>
<td>COPD-related QoL</td>
<td>No differences between groups in SGRQ-A at 1 month</td>
<td>1 fair-quality RCT(^60)</td>
</tr>
<tr>
<td></td>
<td>Self-assessment of health</td>
<td>No differences between groups in self-assessment of health at 1 month</td>
<td>1 fair-quality RCT(^60)</td>
</tr>
<tr>
<td></td>
<td>Illness severity</td>
<td>No differences between groups in illness severity at 1 month</td>
<td>1 fair-quality RCT(^60)</td>
</tr>
<tr>
<td>KQ2: Chronic disease indicators</td>
<td>FEV1 and FEV1/FVC</td>
<td>Periodontal tx group had improved FEV1 and FEV1/FVC compared to no tx group at 2 yrs</td>
<td>1 fair-quality RCT(^49)</td>
</tr>
<tr>
<td>KQ3: Health care utilization and costs</td>
<td>Doctor’s visits</td>
<td>Reductions in doctor’s visits in both intervention and control groups at 1 month and Periodontal tx associated with lower annual medical costs than no tx</td>
<td>1 fair-quality RCT(^60) 1 poor-quality retrospective cohort study(^62)</td>
</tr>
<tr>
<td></td>
<td>Costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KQ4: Harms</td>
<td>Adverse events</td>
<td>No adverse events in either periodontal or no tx groups at 1 month</td>
<td>1 fair-quality RCT(^60)</td>
</tr>
</tbody>
</table>

All results represent differences between periodontal treatment and no treatment groups at follow-up unless otherwise specified.

Key: COPD=Chronic obstructive pulmonary diseases, Tx=Treatment, Yrs=Years, RCT=Randomized controlled trial, QoL=Quality of life, SGRQ-A= St. George’s Respiratory Questionnaire
SUMMARY AND DISCUSSION

We conducted a rapid review to synthesize evidence on benefits and harms of detection and treatment of dental problems (specifically, periodontal disease) among those with T2D, CVD, cerebrovascular disease, or COPD. Although multiple reviews have found a link between periodontal disease and chronic disease, it remains unclear whether treatment for periodontal disease can meaningfully improve chronic disease outcomes and reduce healthcare utilization and associated costs.

This review found that periodontal disease treatment may improve chronic disease outcomes for those with COPD. Results from 1 fair-quality RCT and 1 fair-quality non-randomized, controlled trial suggest periodontal treatment may improve lung function and reduce the frequency of exacerbations at 1 and 2 years compared to no treatment. Another fair-quality RCT found no adverse events within a month of periodontal treatment. However, in this short study, periodontal treatment did not reduce the number of doctor’s visits after treatment, nor did it appear to improve quality of life, self-assessment of health, or illness severity. It is possible that these discordant findings are due to the shorter follow-up period of this study (i.e., the effect of periodontal treatment on some COPD outcomes may take longer than 1 month to become apparent). A poor-quality retrospective cohort study adds additional evidence indicating those who receive periodontal treatment have lower annual medical costs than those who do not receive treatment; however, results may have been confounded if the control group included people who were periodontally healthy.

Results from moderate- and high-quality SRs indicate periodontal treatment likely improves measures of chronic disease severity and inflammation (e.g., HbA1c, fasting blood glucose, total cholesterol, triglycerides, CRP) compared to no treatment among those with T2D or cardiovascular disease in the short term (3-4 months). However, improvements do not seem to persist beyond 6 months. This may be due to the fact that periodontal treatment is meant to be a continuous preventive intervention (i.e., scaling and root planing followed by routine check-ups and addressing subsequent problems that arise). A single periodontal treatment session or group of sessions may therefore be insufficient to produce durable improvement in chronic disease indicators.

Evidence is unclear on whether periodontal treatment reduces the risk of diabetes and CVD-related complications. For those with T2D, evidence from a single fair-quality retrospective cohort study indicates that periodontal treatment may reduce the risk of heart failure compared to no treatment. However, studies on myocardial infarction and stroke risk among those with T2D found conflicting results, with some studies indicating no difference in risk and others indicating lower risk among who received periodontal treatment. Additionally, a simulation study of people with T2 diabetes projected that expanding periodontal treatment would lead to improvements in diabetes-related complications. Authors of this study made important assumptions about the connection between periodontal treatment and diabetes outcomes that have not been directly evaluated. These assumptions could have led to findings that were favorable towards periodontal treatment.

For those with hypertension or atherosclerosis, evidence from a single, poor-quality retrospective cohort study indicates that periodontal treatment may reduce stroke risk. However, a self-controlled case series indicated that individuals’ risk for stroke and myocardial infarction
increased after periodontal treatment when compared to baseline. It is possible the invasive nature of periodontal disease treatment triggers inflammation or releases bacteria into the blood stream, the effect of which is a temporary increase in vascular inflammation and/or atherosclerosis that leads to higher risk of cardiovascular-related adverse events. \(^{54,70}\) However, a 2011 letter published by Harvard Health that discusses this study pointed out that although the relative risk of stroke and myocardial infarction was higher after periodontal treatment than at baseline, the absolute risk of these events was low. \(^{70,71}\) Both this letter and a 2010 news article by Consumer Reports \(^{70}\) also pointed out that participants may have discontinued the use of NSAIDS, blood thinners, or antiplatelet medications to reduce bleeding due to periodontal treatment, and consequently these patients’ cardiovascular risk may have been heightened. Authors of the case series conducted sensitivity analyses to assess whether medication use may have confounded results but acknowledged their data on medications may have been insufficient to rule out confounding.

Findings on costs of periodontal treatment versus no treatment for people with T2D, coronary artery disease, or cerebrovascular disease are also unclear, with some studies \(^{52,57,61-63}\) indicating periodontal treatment contributes to reductions in costs and other studies \(^{51,59,64}\) finding no significant difference or higher medical costs associated with periodontal treatment. One poor-quality retrospective cohort study \(^{57}\) reported periodontal treatment was associated with lower inpatient admissions for those with T2D, coronary artery disease, or cerebrovascular disease, while another \(^{61}\) conducted in those with T2D found no significant differences between groups in total outpatient physician visits, likelihood of a hospitalization, or occurrences of emergency room visits. A major limitation of many of these studies is that the purportedly “no treatment” control groups were poorly described and may have included people who were periodontally healthy. It is reasonable to expect people who are periodontally healthy to have lower health care costs than those who have periodontal disease, and the inclusion of healthy individuals in control groups assumed to represent individuals with periodontal disease not receiving treatment could leads to biased or inaccurate findings. An additional consideration in the applicability of these studies is that several included the costs of providing periodontal treatment. Within the VA’s current pilot program, the VA would not bear the costs of periodontal treatment, which means that the costs measured in included studies are not the same as those incurred by the VA (eg, the costs associated with facilitating access to periodontal treatment or treating dental emergencies subsequent to untreated dental conditions).

Finally, we found some evidence that the balance of benefits and costs may differ by individual patient characteristics. For example, in 1 study \(^{51}\) that reported periodontal treatment was associated with higher medical costs compared to no treatment, authors noted that periodontal treatment was most cost-effective in those with higher HbA1c (who have more to gain from periodontal treatment-associated improvements in HbA1c) and those who are older (who have lower lifetime costs of periodontal treatment). Another study \(^{58}\) found that those with poorly controlled T2D (HbA1c \(\geq 7\%\)) who underwent periodontal treatment experienced significant improvements in OHRQoL compared to controls, while those with well-controlled T2D (HbA1c<7%) who underwent periodontal treatment experienced no improvements compared to controls.
LIMITATIONS

There are limitations to our rapid review methodology and to included SRs and primary studies.

Rapid Review Limitations

The primary limitation of our rapid review methodology is that we prioritized synthesis of the best available evidence, rather than all available evidence. This approach included: 1) synthesizing the 8 most recent and relevant SRs rather than all 25 SRs that met inclusion criteria; 2) conducting primary study searches to address gaps in the SR literature and primary studies published since the end date of prioritized SRs’ searches rather than all possible primary studies; and 3) having a single reviewer assess study eligibility, study quality, and strength of evidence with second reviewer checking instead of dual, independent review. It is possible that because of these steps, we missed eligible studies or eligible data; however, we likely captured the most recent and directly relevant data available on this topic.

Limitations of Included Studies

As discussed in the Results section, only 2 of the 8 prioritized SRs were high quality. Four others were moderate quality, 1 was low quality, and 1 was critically low quality. Common methodological limitations of SRs included not searching for grey literature, no publicly available protocol, no discussion of individual studies’ risk of bias, and lack of information on quality assessment and data extraction processes. Among the 21 primary studies, none were high quality, 13 were fair quality, 5 were poor quality, and 3 were not evaluated formally because they lacked a separate control group (1 was a self-controlled case series and 2 were modeling studies). The most significant limitations of RCTs were that patients and providers were aware of group assignment (unblinded). Among other types of controlled studies, treatment or control groups were poorly defined, there were potentially important differences between groups at baseline, or there was a high risk that confounders could have influenced results.

GAPS AND FUTURE RESEARCH

We generally found unclear evidence from studies with important methodological limitations, suggesting a need for better-conducted studies on this topic. Below we provide specific recommendations for future research:

- **Populations:** There is limited available evidence on the relation between periodontal treatment and chronic disease outcomes for those with cerebrovascular disease. Given periodontal treatment may temporarily increase the risk of adverse events such as myocardial infarction and stroke, researchers should carefully select participants for whom the long-term benefits of periodontal treatment are likely to outweigh the short-term risks. Among those with T2D, CVD, and COPD, researchers should evaluate for which subgroups of patients does periodontal treatment improve chronic disease outcomes the most. We found evidence suggesting particular subgroups of patients with T2D (i.e., those with HbA1c levels ≥ 7% or older adults) may benefit the most from periodontal treatment. Similarly, researchers should evaluate whether outcomes for those with CVD or COPD vary by patient characteristics (e.g., age, sex, race/ethnicity), disease
severity, and whether patients have single versus multiple chronic diseases.

- **Interventions:** This review focused on periodontal treatment as it was the most well-evidenced intervention with respect to impact on chronic disease outcomes. We did not evaluate other interventions that fall on the potential causal pathway shown in Figure 1 and that may indirectly affect chronic disease outcomes, such as routine dental cleanings. Along these lines, researchers of the Care Coordination for Dental Benefits program may be interested in evaluating less-direct but clinically important questions such as whether referral to dental care improves chronic disease outcomes and their associated costs. In this case, it would be important to track whether referral to dental care results in increased receipt of dental services, what kinds of services are delivered (e.g., routine cleanings, tooth extraction, filling cavities, scaling and root planing, and/or surgery), and whether participants continue to receive dental services on a regular basis. Important cointerventions that should be measured include participants’ oral hygiene behaviors (e.g., teeth brushing, flossing, attending routine visits as recommended), as well as other interventions that may affect chronic disease outcomes (e.g., medications and lifestyle interventions).

- **Comparators:** If the primary intervention of interest is referral to dental care services, the primary comparator of interest is no referral or delayed referral. For both intervention and control groups, it would be important to measure and account for participants having private dental insurance and/or receiving dental services outside the VA’s referral program.

- **Outcomes:** Because there is limited or unclear evidence on the relation of periodontal treatment with chronic disease-related complications, health care utilization, and costs, these outcomes should be evaluated in future research. Although periodontal treatment appears to have only a short-term effect on HbA1c (and therefore is unlikely to lead to long-term reductions in complications associated with poorly controlled HbA1c such as retinopathy and neuropathy), it is important to measure this outcome to rule out the possibility that periodontal treatment may inadvertently lead to increased complications. It is also important to measure cardiovascular and cerebrovascular disease-related outcomes such as myocardial infarction and stroke. In terms of health care utilization and costs, researchers should consider rare but expensive health care events (e.g., ED visits and hospitalization for chronic disease-related complications) as well as common but less expensive health care events (e.g., costs of medications, number/frequency of primary and specialty care visits). Additionally, VA researchers should evaluate relevant costs, given that the VA does not bear the costs of periodontal treatment in its pilot program.

- **Timing:** Future studies should assess outcomes at both shorter (3 and 6 month) and longer-term (1+ years) time points for all 4 chronic disease populations. For rare outcomes such as myocardial infarction and stroke, multiple years of follow-up may be required to detect any difference between periodontal treatment and no treatment groups.

- **Settings:** Dental and medical care have long been provided in separate settings; however, there is increasing interest in better coordinating medical and dental care to improve patient outcomes. For example, in 2019 the US Department of Health and Human Services (HHS) awarded $85 million to nearly 300 health centers to expand their oral
health service capacity to help improve patients’ overall health and well-being. The VA is an ideal place to test the effect of a medical-dental care coordination program, as Veterans are generally older and have more comorbidities than the general population (suggesting dental services have a greater than average potential to improve chronic disease outcomes). The VA also has an existing care coordination infrastructure in the form of the Patient Aligned Care Team (PACT) program, which could be expanded to include medical-dental care coordination.

- **Study Designs:** A hybrid effectiveness-implementation trial design is 1 option for evaluating VA’s Care Coordination for Dental Benefits program, given the intervention will be simultaneously implemented and evaluated. Researchers may consider randomizing VA sites to referral or no referral/delayed referral groups. This more limited implementation may also be important because care coordination interventions require dedicated skilled staff time to coordinate care, as well as the development and maintenance of relationships with community-based dental providers. If it is not feasible to randomize sites, a prospective cohort study that carefully matches intervention and control group participants and measures and adjusts for potential cointerventions and confounders, would be another viable option.

**CONCLUSIONS**

Among people with COPD, periodontal treatment may improve lung function and reduce exacerbations at 1-2 years, as well as reduce annual medical costs. Among people with diabetes or cardiovascular disease, periodontal treatment likely leads to improvements in some measures of chronic disease severity and inflammation at 3-4 months, but benefits do not seem to persist beyond 6 months. Results are unclear on the relation between periodontal treatment and chronic disease outcomes for those with cerebrovascular disease. Results are also unclear on the relation between periodontal treatment and medical costs and risk of chronic disease complications among those with diabetes, cardiovascular disease, or cerebrovascular disease.
ACKNOWLEDGMENTS

This topic was developed in response to a nomination by the Partnered Evidence-Based Policy Resource Center (PEPReC) for the purpose of informing the implementation and evaluation of the Veterans Innovation Center (VIC) Care Coordination for Dental Benefits demonstration program. The scope was further developed with input from the topic nominators (ie, Operational Partners) and the ESP Coordinating Center.

In designing the study questions and methodology at the outset of this report, the ESP consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

The authors gratefully acknowledge Mark Helfand, MD, MPH, MS for input on review scope, Payten Sonnen for help with data extraction and editorial review, and Julia Haskin, MA for her editorial review, as well as the following individuals for their contributions to the project:

**Operational Partners**

Operational partners are system-level stakeholders who have requested the report to inform decision-making. They recommend Technical Expert Panel (TEP) participants; assure VA relevance; help develop and approve final project scope and timeframe for completion; provide feedback on draft report; and provide consultation on strategies for dissemination of the report to field and relevant groups.

**Melissa Garrido, PhD**  
Associate Director, Partnered Evidence-Based Policy Resource Center (PEPReC)  
Boston VA Healthcare System
REFERENCES


53. Peng CH, Yang YS, Chan KC, Kornelius E, Chiou JY, Huang CN. Periodontal Treatment and the Risks of Cardiovascular Disease in Patients with Type 2 Diabetes: A Retrospective Cohort Study. *Internal Medicine*. 2017;56(9):1015-1021.


